Clinical Trial Update: 68Ga-DOTA-TATE PET/CT Imaging in NETs [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating 68Ga-DOTA-TATE PET/CT imaging for neuroendocrine tumors and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 68Ga-DOTA-TATE (gallium-68 DOTA-TATE)

Snippet

Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Conditions: Neuroendocrine Tumors | Phase 3 | Status: RECRUITING